FIELD: biotechnology.
SUBSTANCE: invention relates to an isolated antibody or its antigen-binding part that specifically binds to the alpha chain of the human IL-7 receptor (IL-7R), as well as to an immunoconjugate and a kit containing it.
EFFECT: invention is effective for treating an inflammatory disease or an autoimmune disease.
17 cl, 29 dwg, 18 tbl, 14 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ADVANCED PROCOAGULANT ANTIBODIES | 2019 |
|
RU2810748C2 |
| MONOCLONAL ANTIBODY TO NAV1.7 | 2019 |
|
RU2776821C2 |
| ANTI-SIRPα ANTIBODY AND USE THEREOF | 2021 |
|
RU2822496C1 |
| ANTIBODIES DIRECTED TO CD127 | 2015 |
|
RU2734076C2 |
| C3 BINDING AGENTS AND METHODS OF THEIR USE | 2019 |
|
RU2802307C2 |
| PD-1 BINDING ANTIBODIES AND METHODS OF THEIR USE | 2019 |
|
RU2812280C1 |
| ANTI-CEACAM1 ANTIBODY AND ITS APPLICATION | 2018 |
|
RU2754876C2 |
| ANTIBODIES BINDING TO PD-1 AND THEIR APPLICATIONS | 2019 |
|
RU2773758C2 |
| ANTI-SIRPα ANTIBODIES | 2018 |
|
RU2771174C2 |
| CYTOTOXICITY-INDUCING THERAPEUTIC AGENT | 2015 |
|
RU2743464C2 |
